IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Reports Third Quarter Financial Results and Provides Corporate Update
29 oct. 2020 16h36 HE | Idera Pharmaceuticals, Inc.
EXTON, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces New U.S. Patent Coverage for Tilsotolimod Through September 2037
28 sept. 2020 08h45 HE | Idera Pharmaceuticals, Inc.
EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
15 sept. 2020 07h18 HE | Idera Pharmaceuticals, Inc.
Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Reports Second Quarter Financial Results and Provides Corporate Update
04 août 2020 16h10 HE | Idera Pharmaceuticals, Inc.
EXTON, Pa., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Private Placement of up to $20.0 Million
15 juil. 2020 08h05 HE | Idera Pharmaceuticals, Inc.
EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors providing for...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Preliminary Data From and Planned Continuation of the ILLUMINATE-206 Trial for the Treatment of Micro-Satellite Stable Colorectal Cancer
02 juin 2020 08h15 HE | Idera Pharmaceuticals, Inc.
EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of ...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Change of Location for 2020 Annual Meeting of Stockholders
01 mai 2020 08h00 HE | Idera Pharmaceuticals, Inc.
EXTON, Pa., May 01, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today provided notice of a change in the location for its 2020 Annual Meeting of...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
30 avr. 2020 16h35 HE | Idera Pharmaceuticals, Inc.
EXTON, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the first quarter ended...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Tilsotolimod Program Updates to be Presented at AACR Virtual Annual Meeting 2020
23 avr. 2020 07h30 HE | Idera Pharmaceuticals, Inc.
EXTON, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that updates on ILLUMINATE-206 and ILLUMINATE-101, two studies investigating...
IDERA_5C_RGB-01.jpg
Idera Pharmaceuticals Announces Final Clinical Safety and Efficacy Data from ILLUMINATE-204 Trial in Advanced Melanoma
21 avr. 2020 07h30 HE | Idera Pharmaceuticals, Inc.
– Overall response rate of 22% –– Disease control rate of 71% –– Median overall survival of 21 months –– Key topline data from ILLUMINATE-301 expected in Q1 2021 – EXTON, Pa., April 21, 2020 ...